Date: 2017-01-24
Type of information: Nomination
Compound:
Company: CTI BioPharma - previously known as Cell Therapeutics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: • On January 24, 2017, CTI BioPharma announced that Michael A. Metzger has been appointed a Director of CTI BioPharma. Mr. Metzger brings extensive experience leading and growing companies in the biopharmaceutical industry over the last 20 years. Mr. Metzger is currently president and chief operating officer of Syndax Pharmaceuticals, a publicly traded immuno-oncology biopharmaceutical company. He has served as president and chief executive officer of Regado Biosciences, a former publicly traded biotechnology company, from 2013 to 2015, where he oversaw the company's successful merger with Tobira Therapeutics in 2015 and acted as an advisor to Tobira during its subsequent sale to Allergan in 2016. Previously, Mr. Metzger served as executive vice president and chief operating officer at Mersana Therapeutics, a privately held biotechnology company developing novel immunoconjugate therapies for cancer, from 2011 to 2013 and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, Inc. from 2006 to 2011. Mr. Metzger served as vice president corporate development at Onconova Therapeutics, Inc., from 2001 until 2006, and was a managing director at MESA Partners, a venture capital firm, from 1997 to 2001.He holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business."
Financial terms:
Latest news:
